|Bid||10,100.00 x 0|
|Ask||11,348.00 x 0|
|Day's range||11,074.00 - 11,230.00|
|52-week range||8,090.32 - 11,540.00|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||104.47|
|Forward dividend & yield||2.22 (2.00%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
WILMINGTON, Del., November 30, 2022--AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022.
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with
AstraZeneca (Thailand) Co., Ltd., was recently honoured with two accolades in the categories of Industry Champions of the Year and Community Initiative at the Asia Corporate Excellence & Sustainability Awards 2022 (ACES Awards 2022).